GSK vs Merck
GSK and MRK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GSK and MRK compare
Merck grew revenue faster over the last twelve months (4.6% versus 4.1% for GSK).
GSK keeps more of each dollar of sales as profit, with a net margin of 17.5% compared with 4.8% at Merck.
Merck pays a dividend yielding 2.3%; GSK does not pay one.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GSK | MRK |
|---|---|---|
| Size and price | ||
| Market cap | – | $361B |
| Share price | $49.51 | $146.33 |
| Change, 1 year | 7.8% | 68.1% |
| Change, 5 years | −7.1% | 79.3% |
| Beta (5Y) | 0.26 | 0.22 |
| Employees | 500K | 75K |
| StockData Score | ||
| Total score | 9 | 9 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 4 (better) | 3 |
| Health score | 3 | 3 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 117× |
| P/S | – | 5.4× |
| P/B | – | 8.6× |
| P/FCF | – | 22.5× |
| PEG | – | 13.88 |
| FCF yield | – | 4.4% |
| Fair value | – | $42.82 |
| Margin of safety | – | −242% |
| Growth | ||
| Revenue growth (TTM) | 4.1% | 4.6% (better) |
| Revenue growth, 5Y average | 6.0% | 9.4% (better) |
| Net income growth (TTM) | 122% (better) | −80.7% |
| EPS growth (TTM) | 123% (better) | −80.7% |
| EPS growth, 5Y average | −0.54% | 21.2% (better) |
| Profitability | ||
| Gross margin | 72.4% | 73.0% (better) |
| Operating margin | 24.3% | – |
| Net margin | 17.5% (better) | 4.8% |
| FCF margin | 19.6% | 24.1% (better) |
| Return on equity | 38.0% (better) | 7.0% |
| Return on invested capital | 23.4% | – |
| Financial health | ||
| Debt / equity | 1.08 (better) | 1.29 |
| Net debt / EBITDA | 1.40 | – |
| Interest coverage | 11.3× | – |
| Current ratio | 0.82 | 1.32 (better) |
| Altman Z-score | – | 3.74 |
| Piotroski F-score | 9 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | – | 2.3% |
| Payout ratio | 44.9% | 262% |
| Years of dividend growth | – | 15 |
| Dividend growth, 5Y average | – | 5.8% |
| Buyback yield | – | 1.2% |
| Shareholder yield | – | 3.5% |
| Ownership | ||
| Held by institutions | 8.0% | 80.3% |
| Held by insiders | 0.05% | 0.05% |
| Insider net buying, 12 months | – | −$72.0M |
| Superinvestors holding | 1 | 4 (better) |
| Short interest, % of float | – | 1.1% |
Go deeper
- GSK stock overview
- GSK income statement
- GSK valuation and score
- MRK stock overview
- MRK income statement
- MRK valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.